p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas.
about
Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumoursNottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?Cancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesP-cadherin and the journey to cancer metastasisQuantitative image analysis of immunohistochemical stains using a CMYK color model.Metaplastic breast carcinomas are basal-like tumours.Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions.Elevated Krüppel-like factor 4 transcription factor in canine mammary carcinomaBiology, metastatic patterns, and treatment of patients with triple-negative breast cancer.Possible Relationship between Basal-Like Breast Carcinoma and AgeMolecular insights on basal-like breast cancer.Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.Triple-negative breast carcinomas are a heterogeneous entity that differs between young and old patientsSerological analysis of SEREX-defined medullary breast carcinoma-associated antigens.Lipid-rich histology in a basal-type immuno-profile breast carcinoma: a clinicopathological histochemical and immunohistochemical analysis of a caseMolecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer.Aberrant P-cadherin expression is associated to aggressive feline mammary carcinomasCorrelation of tumor-infiltrating lymphocytes to histopathological features and molecular phenotypes in canine mammary carcinoma: A morphologic and immunohistochemical morphometric studyPatterns of recurrence after breast-conserving treatment for early stage breast cancer by molecular subtypeManagement options in triple-negative breast cancerOverexpression of Raf-1 in basal-like carcinoma of the breast: correlation with clinicopathology and prognosis.Establishment of a mammary carcinoma cell line from Syrian hamsters treated with N-methyl-N-nitrosourea.From milk to malignancy: the role of mammary stem cells in development, pregnancy and breast cancer.Triple-Negative Breast Cancer: Clinical and Histological Correlations.Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survivalBasal-like breast carcinomas: clinical outcome and response to chemotherapy.Cadherin cell adhesion system in canine mammary cancer: a review.Role of p63 in Development, Tumorigenesis and Cancer ProgressionA comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas.P-cadherin expression in breast cancer: a review.Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast.A MicroRNA196a2* and TP63 circuit regulated by estrogen receptor-α and ERK2 that controls breast cancer proliferation and invasiveness properties.Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast.p16 expression correlates with basal-like triple-negative breast carcinomaComedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroupDisrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy.Opinion on moderate/low cancer genetic risk markers in medical practice including comment on the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tu
P2860
Q21030553-0316193E-5DE4-4C3C-9372-E332C9FCF120Q21261291-195B9130-9839-42B7-A8E7-9A844505C798Q26743510-9CC332AF-660C-46EB-BBCC-CBF911FEFB3FQ26781906-4E0D08BC-6FD8-4C1A-84FA-FD6060675F93Q30479054-636AF63B-3DAE-439E-B6D2-BAF16E409B27Q33250228-7523C562-389E-49C0-AEDC-5B1F4F7ED8C4Q33690078-6DD6EE44-276F-4AD4-9F36-B76855D5853CQ34042124-0509DA21-9D32-4AE5-BB46-7C09ABBC8315Q34058510-E15E2661-8234-4405-BBFC-5CE7D566E2D2Q34095838-8953D5B8-F674-44EB-B9E9-3997444A5EC1Q34123314-7986BE30-AC66-4119-9823-67AD5871BBACQ34245323-A932FF7B-5FCC-4C4B-89E7-0D98B4F790B6Q34275213-227AA7A0-95A4-45E4-A6FD-F23770F413B1Q34308955-B70F895C-7D35-48E4-A84D-DCF9B9BA927DQ34364673-64B6C7D3-B27A-44BE-90E7-EE78B4D5960EQ34577467-47555F6B-6D8F-428B-9823-9DFB0AFA4485Q34577709-1BBE7DC0-0ADE-46FB-9792-2B9FFE9888E3Q34622433-CCC2CAB0-84F7-41C3-A208-9E23C81A3EA3Q35003157-01159233-3073-4966-85B3-5650EF057B60Q35142129-44B658C2-F947-4A54-850D-5C55FE817058Q35155460-D6EA3DD3-9864-4F06-8309-B0E731508D79Q35165561-061DBA42-B78E-451D-BE29-1663136E2A1AQ35256614-84BCFFC8-494A-4AFB-9A28-2A2324EB069CQ35348210-D7A98D2B-5504-4A90-9C30-44497093064BQ35576252-58A1A3CB-A2EC-44AB-AC78-43904F71F92FQ35749421-6A9B355F-C518-45EB-9851-D49396F6E879Q35770209-B1FC71E6-B21A-47AF-8E50-C4543B9A27CAQ36204016-9796CA52-9E15-4714-A9D9-19D453FA3822Q36284945-A30AF0AC-E1C1-40D4-9D87-60AAAA357ACEQ36369621-5E5B52A6-F5D2-4545-B25B-BA1A7CE84D08Q36458759-912EFC71-C97C-4737-9915-741C7513DD37Q36536620-7E497368-CDFB-4808-8DB9-7424A83E5716Q36636769-09E0091F-3BF8-4E9C-9E62-5A187E8A13D7Q36845026-2B08ED16-571A-4171-8CF7-B23D7147817FQ36863171-8B1CA9AE-6E80-4C28-B459-AB136AB27E2AQ37016553-09A4E8A6-963C-4883-A94D-C893E9B2AB4DQ37057268-34AFCB11-DAE5-4320-B83F-4A446C794A29Q37081132-615DF649-C8B4-406C-825E-ECBFA0FCBD3BQ37206247-A30BC616-60E7-4B57-801E-8250DBB7B4A0Q37326661-30944FAD-3D17-4CB5-A478-DD1CEDD6A5FE
P2860
p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
p63, cytokeratin 5, and P-cadh ...... henotype in breast carcinomas.
@en
p63, cytokeratin 5, and P-cadh ...... henotype in breast carcinomas.
@nl
type
label
p63, cytokeratin 5, and P-cadh ...... henotype in breast carcinomas.
@en
p63, cytokeratin 5, and P-cadh ...... henotype in breast carcinomas.
@nl
prefLabel
p63, cytokeratin 5, and P-cadh ...... henotype in breast carcinomas.
@en
p63, cytokeratin 5, and P-cadh ...... henotype in breast carcinomas.
@nl
P2093
P2860
P1433
P1476
p63, cytokeratin 5, and P-cadh ...... henotype in breast carcinomas.
@en
P2093
Irina Matos
Luiz Carlos Zeferino
Marcelo Alvarenga
Rozany Dufloth
P2860
P2888
P304
P356
10.1007/S00428-005-0010-7
P577
2005-10-19T00:00:00Z
P5875
P6179
1048189318